Page 23 of 35

DR10.8-9 | Urethral Discharge Diagnosis and Syndromic Management — SDL Guide (Part 2)

Interpretation of Clinical and Laboratory Findings

A four-panel medical infographic compares gonococcal urethritis, non-gonococcal urethritis, and mixed infection using smear findings, clinical features, testing, and treatment principles. — **Panel A:** Comparison of gonococcal urethritis, non-gonococcal urethritis, and mixed infection with neutrophils, intracellular Gram-negative diplococci, discharge type, dysuria severity, and likely organism.. **Panel B:** Microscopy decision rule showing significant urethritis threshold of five or more neutrophils per high-power oil-immersion field and interpretation of intracellular diplococci.. **Panel C:** Confirmatory laboratory testing pathway showing urethral swab, culture, NAAT, organism confirmation, and antimicrobial susceptibility testing.. **Panel D:** Clinical management principle showing syndromic treatment for both Neisseria gonorrhoeae and Chlamydia trachomatis, with note on ceftriaxone-based therapy and resistance monitoring..

Interpreting the smear correctly tells you what you are dealing with, though it never changes the principle of treating both organisms. The presence of neutrophils with intracellular Gram-negative diplococci is a positive presumptive diagnosis of gonococcal urethritis; a threshold of about five or more neutrophils per high-power oil-immersion field supports significant urethritis. If you see neutrophils without intracellular diplococci, the picture is one of non-gonococcal urethritis, most often chlamydial. A mixed infection — both present — is common and expected. Where no smear is available, you treat syndromically for both. Culture or nucleic-acid amplification testing, where accessible, can confirm the organism and provide antimicrobial susceptibility, which matters because of the worsening trend of gonococcal resistance to cephalosporins documented by global surveillance (the WHO gonococcal antimicrobial surveillance programme); current first-line treatment remains ceftriaxone-based, but susceptibility must be monitored.

A comparison diagram contrasts gonococcal urethritis, non-gonococcal urethritis, and mixed infection using smear findings, discharge type, dysuria severity, organisms, and syndromic treatment components. — **Panel A:** Comparison table showing GC urethritis, NGU, and mixed infection with smear findings, discharge type, dysuria severity, organism, and first-line treatment component.. **Panel B:** Microscopy interpretation pointers showing PMNs with intracellular Gram-negative diplococci, PMNs without diplococci, and the no-smear syndromic pathway.. **Panel C:** Clinical rationale for treating both gonorrhoea and chlamydia in urethral discharge syndrome because clinical overlap and co-infection are common..

Interpretation pointers:
- PMNs + intracellular Gram-negative diplococci → gonococcal urethritis
- PMNs without diplococci → non-gonococcal (commonly chlamydial) urethritis
- Mixed infection common; no smear available → treat both syndromically
- Watch for rising gonococcal cephalosporin resistance (verify current susceptibility data)

SELF-CHECK

Why does NACO syndromic management of urethral discharge (Kit 1) routinely combine an agent against Neisseria gonorrhoeae with an agent against Chlamydia trachomatis?

A. Because the two drugs are cheaper when bought together

B. Because gonococcal and chlamydial infections frequently coexist and cannot be reliably separated clinically, so treating both at first contact prevents undertreated co-infection

C. Because chlamydia is resistant to all single agents

D. Because the gonococcus is always resistant to cephalosporins

Reveal Answer

Answer: B. Because gonococcal and chlamydial infections frequently coexist and cannot be reliably separated clinically, so treating both at first contact prevents undertreated co-infection

Gonococcal and chlamydial urethritis frequently coexist and overlap clinically, so syndromic management treats both at the first visit (e.g. cefixime or ceftriaxone for gonorrhoea plus azithromycin or doxycycline for chlamydia — per current NACO guidance). This prevents the common error of treating only the visible gonococcal infection and leaving chlamydia untreated.

Syndromic Management, Counselling, and Partner Treatment

comparison table: NACO Kit 1 (grey) — drugs, doses, route, duration for GC component vs NGU component; partner management; counselling checklist points; per current NACO STI/RTI guidelines — click to enlarge

Applied management brings together drugs, partner treatment, and counselling into a single first-contact intervention, and under NACO this is Kit 1 (grey) — per current NACO guidance, with exact drugs and doses to be confirmed against the latest national protocol. The principle is to treat both organisms together at the first visit, without waiting for a smear result: an agent active against Neisseria gonorrhoeae (a cephalosporin such as cefixime or ceftriaxone) plus an agent active against Chlamydia trachomatis (azithromycin or doxycycline). Because gonococcal cephalosporin resistance is rising, ceftriaxone-based regimens are favoured and susceptibility should be monitored where data exist. Management is incomplete without the public-health package: treat the sexual partner(s) regardless of whether they have symptoms, promote and provide condoms, counsel the patient to complete the course and abstain from sex during treatment, offer HIV testing, and arrange follow-up (typically around 7 days) to confirm resolution. Persistent or recurrent discharge after correct treatment prompts reassessment for resistance, reinfection, or Mycoplasma genitalium.

Three-panel infographic comparing NACO Kit 1 grey treatment for gonococcal and non-gonococcal urethral discharge, partner treatment, counselling points, and 7-day reassessment causes. — **Panel A:** Comparison table for NACO Kit 1 grey showing GC component, NGU/chlamydia component, organisms, drugs, doses, oral route, single-dose duration, and resistance-related ceftriaxone note.. **Panel B:** Partner management flow showing index patient, sexual partners, partner treatment regardless of symptoms, condom promotion, abstinence during treatment, and reinfection prevention.. **Panel C:** Counselling checklist with course completion, abstinence, condom use, HIV/syphilis testing, follow-up, and persistent discharge reassessment for reinfection, gonococcal resistance, or Mycoplasma genitalium..

Management essentials:
- NACO Kit 1 (grey): treat GC + chlamydia together at first contact (e.g. cefixime/ceftriaxone + azithromycin/doxycycline)
- Favour ceftriaxone-based regimens given rising gonococcal resistance; monitor susceptibility
- Treat partner(s) regardless of symptoms; promote condoms
- Counsel: complete course, abstain during treatment, offer HIV testing, follow up ~7 days

SELF-CHECK

A man treated for urethral discharge returns at 7 days with persistent symptoms despite confirming he completed his medication. Which considerations are most appropriate?

A. Reassure him it is psychological and discharge without action

B. Reassess for reinfection (untreated partner), gonococcal antimicrobial resistance, or Mycoplasma genitalium, and manage accordingly

C. Double the original antibiotic dose without any reassessment

D. Conclude the original diagnosis was wrong and stop all treatment

Reveal Answer

Answer: B. Reassess for reinfection (untreated partner), gonococcal antimicrobial resistance, or Mycoplasma genitalium, and manage accordingly

Persistent or recurrent discharge after correct treatment should prompt reassessment for reinfection from an untreated partner, rising gonococcal cephalosporin resistance, or Mycoplasma genitalium (which can resist standard NGU therapy). This is why partner treatment, counselling, and follow-up are integral to syndromic management.

Self-Assessment: Urethral Discharge Diagnosis and Management

A four-panel medical education diagram summarizes urethral discharge diagnosis, Gram smear appearance of gonorrhoea, non-gonococcal causes, and complete first-contact STI management including partner treatment and resistance awareness. — **Panel A:** Non-explicit male lower urinary tract silhouette, highlighted urethra, urethral discharge icon, dysuria, first-contact presumptive treatment pathway. **Panel B:** Gram smear showing polymorphonuclear leukocyte, Neisseria gonorrhoeae, Gram-negative intracellular diplococci. **Panel C:** Common non-gonococcal urethritis causes: Chlamydia trachomatis, Mycoplasma genitalium, Ureaplasma urealyticum, co-infection callout. **Panel D:** Management wheel showing Kit 1 cefixime plus azithromycin, dual coverage for gonococcus and chlamydia, partner notification and treatment, abstinence counselling, follow-up, antimicrobial resistance warning.

Before finishing, assess your own command of both the knowledge and the skill, because urethral discharge is a syndrome where a single conceptual gap — forgetting the chlamydial co-infection — translates directly into undertreated patients and continued transmission. Work through the questions below as if you were running an STI clinic, articulating the organism, the smear finding, the kit, and the full counselling package for each. Give particular weight to the two ideas that learners most often drop under time pressure: that you treat both organisms together at first contact, and that partner treatment and follow-up are part of the treatment, not optional extras. Where an answer feels shaky, revisit the relevant section and rehearse it until the reasoning is automatic, because in a busy clinic you will fall back on whatever you have made second nature. Treat any uncertainty as a cue for revision, not a cause for concern.

Self-check questions:
- What organism causes gonococcal urethritis, and what is its appearance on a Gram smear?
- What are the common causes of non-gonococcal urethritis?
- Why does Kit 1 treat both organisms together?
- What is the public-health emerging concern about the gonococcus?
- What partner-treatment and counselling steps complete management?

CLINICAL PEARL

The most common avoidable error in urethral discharge is 'treating what you see' — giving a single shot for the obvious gonococcal discharge and never covering the silent chlamydial co-infection that recurs a week later. Always treat both. And when a patient returns with persistent discharge despite completing treatment, your first three thoughts should be reinfection from an untreated partner, rising gonococcal resistance, and Mycoplasma genitalium — in that order. Partner treatment is not an add-on; it is part of curing your patient.